412044-92-9|CHF 2819|Carbamic acid, (2-ethylphenyl)-, (1R,3aS,8aS)-1,2,3,3a,8,8a-hexahydro-1,3a-dimethyl-1-oxidopyrrolo(2,3-b)indol-5-yl ester, monohydrochloride|-范德生物科技公司

CHF 2819

NMR下载 COA and HPLC MSDS下载
names：
Carbamic acid, (2-ethylphenyl)-, (1R,3aS,8aS)-1,2,3,3a,8,8a-hexahydro-1,3a-dimethyl-1-oxidopyrrolo(2,3-b)indol-5-yl ester, monohydrochloride
CAS号：
412044-92-9
MDL Number：
MF(分子式)： C21H26ClN3O3 MW(分子量)： 403.9
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	CHF 2819
英文别名	CHF 2819; CHF2819; CHF-2819; Ganstigmine hydrochloride; Ganstigmine HCl.
CAS号	412044-92-9
Inchi	InChI=1S/C21H25N3O3.ClH/c1-4-14-7-5-6-8-17(14)23-20(25)27-15-9-10-18-16(13-15)21(2)11-12-24(3,26)19(21)22-18;/h5-10,13,19,22H,4,11-12H2,1-3H3,(H,23,25);1H/t19-,21-,24?;/m0./s1
InchiKey	CVDHRWXJJRBPFA-IEGNKYQISA-N
分子式 Formula	C21H26ClN3O3
分子量 Molecular Weight	403.9
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	CHF 2819(CAS:412044-92-9):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	CHF 2819, also known as ganstigmine hydrochloride, is a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease. CHF 2819 is a selective inhibitor of AChE; it is 115 times more potent against this enzyme than against butyrylcholinesterase (BuChE). Moreover, CHF2819 is more selective for inhibition of central (brain) AChE than peripheral (heart) AChE. In particular, CHF2819 might be a useful therapeutic drug for Alzheimer's disease patients with cognitive impairment accompanied by depression.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Trabace L, Cassano T, Steardo L, Pietra C, Villetti G, Kendrick KM, Cuomo V. Biochemical and neurobehavioral profile of CHF2819, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease. J Pharmacol Exp Ther. 2000 Jul;294(1):187-94. PubMed PMID: 10871311.

[2]Bartolucci C, Siotto M, Ghidini E, Amari G, Bolzoni PT, Racchi M, Villetti G, Delcanale M, Lamba D. Structural determinants of Torpedo californica acetylcholinesterase inhibition by the novel and orally active carbamate based anti-alzheimer drug ganstigmine (CHF-2819). J Med Chem. 2006 Aug 24;49(17):5051-8. PubMed PMID: 16913695.

[3] Jhee SS, Fabbri L, Piccinno A, Monici P, Moran S, Zarotsky V, Tan EY, Frackiewicz EJ, Shiovitz T. First clinical evaluation of ganstigmine in patients with probable Alzheimer's disease. Clin Neuropharmacol. 2003 May-Jun;26(3):164-9. PubMed PMID: 12782920.

[4] Trabace L, Cassano T, Loverre A, Steardo L, Cuomo V. CHF2819: pharmacological profile of a novel acetylcholinesterase inhibitor. CNS Drug Rev. 2002 Spring;8(1):53-69. Review. PubMed PMID: 12070526.

[5] Trabace L, Cassano T, Cagiano R, Tattoli M, Pietra C, Steardo L, Kendrick KM, Cuomo V. Effects of ENA713 and CHF2819, two anti-Alzheimer's disease drugs, on rat amino acid levels. Brain Res. 2001 Aug 10;910(1-2):182-6. PubMed PMID: 11489269.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开